Cathy Andorfer, Ph.D.
About Cathy Andorfer, Ph.D.
Cathy Andorfer, Ph.D., is the Lead US Dermatology Field Medical at Bri, with extensive experience in neurology, rare diseases, and dermatology. She has held significant roles at Dermira, Inc., Biogen, and Mayo Clinic, and is known for her expertise in launching medical products and building field teams.
Current Role at Bri
Cathy Andorfer, Ph.D., serves as the Lead US Dermatology Field Medical. In this position, she is responsible for building and supporting a field medical team. Her work includes supporting the dermatology pipeline, including an oral TYK2 inhibitor for the treatment of psoriasis. She is currently in the process of expanding her team with plans to hire three Regional Associate Directors, two Executive Medical Science Liaisons (MSLs), and a team of twenty MSLs by the end of the year.
Previous Experience at Dermira, Inc.
Cathy Andorfer worked at Dermira, Inc. from 2017 to 2020, where she served in different capacities. As the Senior Director of the Field Medical Team from 2018 to 2020, she focused on the execution and life cycle management of Dermira's products. Before that, she was the Regional Scientific Director from 2017 to 2018. Her tenure at Dermira involved strategic pre-launch activities for Cimzia® for psoriasis and building thought leader and advocacy bases for the treatments for psoriasis, acne, hyperhidrosis, and atopic dermatitis.
Experience at Biogen
From 2011 to 2017, Cathy Andorfer held positions at Biogen, starting as a Medical Science Liaison from 2011 to 2013 and later as the Principal and Senior Medical Science Liaison from 2013 to 2017. During her time at Biogen, she supported the pipeline and marketed treatments for multiple sclerosis, Alzheimer’s disease, and spinal muscular atrophy. She played a significant role in launching seven products, including Avonex® Pen, Tysabri® JCV Assay, Tecfidera®, Plegridy®, Zinbryta, Spinraza®, and Qbrexza®.
Scientific and Academic Background
Cathy Andorfer's academic journey includes a Ph.D. in Neuroscience from Albert Einstein College of Medicine of Yeshiva University, completed between 1998 and 2003. Before this, she attained a Master’s in Biology/Animal Physiology from the University of Notre Dame, completed between 1995 and 1998. Her early career features significant roles such as an Instructor and Translational Scientist at Mayo Clinic, where she worked from 2005 to 2011, and a Postdoctoral Fellow at the Seattle Institute for Biomedical and Clinical Research from 2004 to 2005.
Therapeutic Experience and Clinical Expertise
Cathy Andorfer has extensive therapeutic experience across multiple disciplines, including neurology, rare disease, and dermatology. Her career highlights include launching seven products and supporting strategic planning and clinical programs for various treatments, such as aducanumab for Alzheimer’s disease. Cathy is well-connected with investigators and clinical experts in medical dermatology and neurology, underscoring her broad expertise and significant contributions to the field.